Compare CET & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CET | PGEN |
|---|---|---|
| Founded | 1929 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2013 |
| Metric | CET | PGEN |
|---|---|---|
| Price | $55.20 | $6.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 31.8K | ★ 4.9M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | ★ $6.93 | $228.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.82 | $1.80 |
| 52 Week High | $55.99 | $7.32 |
| Indicator | CET | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 67.59 |
| Support Level | $52.20 | $3.96 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.72 | 0.41 |
| MACD | 0.21 | 0.08 |
| Stochastic Oscillator | 77.74 | 77.58 |
Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.